N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide

C46H46N8O4 — CID 46236070

IUPACN-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
SMILESO=C(NC(C(=O)N1CCCC1c1ncc(C#Cc2ccc(-c3cnc(C4CCCN4C(=O)C(NC(=O)C4CC4)c4ccccc4)[nH]3)cc2)[nH]1)c1ccccc1)C1CC1
InChIInChI=1S/C46H46N8O4/c55-43(33-20-21-33)51-39(31-9-3-1-4-10-31)45(57)53-25-7-13-37(53)41-47-27-35(49-41)24-17-29-15-18-30(19-16-29)36-28-48-42(50-36)38-14-8-26-54(38)46(58)40(32-11-5-2-6-12-32)52-44(56)34-22-23-34/h1-6,9-12,15-16,18-19,27-28,33-34,37-40H,7-8,13-14,20-23,25-26H2,(H,47,49)(H,48,50)(H,51,55)(H,52,56)
InChIKeyOEDPHJLSVGAEOG-UHFFFAOYSA-N
MW774.93 g/mol
LogP6.06
Rot. Bonds11

About N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide

N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide (PubChem CID 46236070) has the molecular formula C46H46N8O4 and a molecular weight of 774.93 g/mol. Its IUPAC name is N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide.

Molecular Properties

Compound NameN-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
PubChem CID46236070
Molecular FormulaC46H46N8O4
Molecular Weight774.93 g/mol
Exact Mass774.36
IUPAC NameN-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
SMILESO=C(NC(C(=O)N1CCCC1c1ncc(C#Cc2ccc(-c3cnc(C4CCCN4C(=O)C(NC(=O)C4CC4)c4ccccc4)[nH]3)cc2)[nH]1)c1ccccc1)C1CC1
InChIInChI=1S/C46H46N8O4/c55-43(33-20-21-33)51-39(31-9-3-1-4-10-31)45(57)53-25-7-13-37(53)41-47-27-35(49-41)24-17-29-15-18-30(19-16-29)36-28-48-42(50-36)38-14-8-26-54(38)46(58)40(32-11-5-2-6-12-32)52-44(56)34-22-23-34/h1-6,9-12,15-16,18-19,27-28,33-34,37-40H,7-8,13-14,20-23,25-26H2,(H,47,49)(H,48,50)(H,51,55)(H,52,56)
InChIKeyOEDPHJLSVGAEOG-UHFFFAOYSA-N
XLogP6.06
TPSA156.18 Ų
H-Bond Donors4
H-Bond Acceptors6
Rotatable Bonds11
Heavy Atoms58
Complexity

Lipinski Rule of Five

2 violations

RuleValue
MW ≤ 500774.93
LogP ≤ 56.06
H-Bond Donors ≤ 54
H-Bond Acceptors ≤ 106

Computed Properties (RDKit)

Structural Alerts{'alert_name': 'triple_bond', 'substructure': 'N/A'}

Analyze N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide?
The IUPAC name of N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide (CID 46236070) is N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide.
What is the SMILES notation for N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide?
The canonical SMILES for N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide is O=C(NC(C(=O)N1CCCC1c1ncc(C#Cc2ccc(-c3cnc(C4CCCN4C(=O)C(NC(=O)C4CC4)c4ccccc4)[nH]3)cc2)[nH]1)c1ccccc1)C1CC1.
What is the InChIKey of N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide?
The InChIKey is OEDPHJLSVGAEOG-UHFFFAOYSA-N. The full InChI is InChI=1S/C46H46N8O4/c55-43(33-20-21-33)51-39(31-9-3-1-4-10-31)45(57)53-25-7-13-37(53)41-47-27-35(49-41)24-17-29-15-18-30(19-16-29)36-28-48-42(50-36)38-14-8-26-54(38)46(58)40(32-11-5-2-6-12-32)52-44(56)34-22-23-34/h1-6,9-12,15-16,18-19,27-28,33-34,37-40H,7-8,13-14,20-23,25-26H2,(H,47,49)(H,48,50)(H,51,55)(H,52,56).
What are the key properties of N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide?
N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide has a molecular weight of 774.93 g/mol, XLogP of 6.06, 11 rotatable bonds, 4 hydrogen bond donors, and 6 hydrogen bond acceptors.
Where does this data come from?
All data for N-[2-[2-[5-[2-[4-[2-[1-[2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethynyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide is sourced from PubChem (CID 46236070), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).